In a research report released on April 10, Huatai Securities highlighted significant advancements in the US FDA's approach to drug development, particularly in monoclonal antibody therapy. The FDA has announced initiatives aimed at reducing, refining, or replacing animal testing requirements. These include the integration of AI-driven toxicity computational models and the utilization of cell lines and organoids for toxicity testing in controlled laboratory environments. The agency plans to initiate a pilot program in 2025, enabling select pharmaceutical companies to forgo animal experiments entirely under supervision, with the anticipation of a comprehensive policy update by 2026. This transformation is poised to propel the application of AI in new drug development, extending its reach beyond chemical synthesis into biological phases, including preclinical and clinical trials. Consequently, innovative pharmaceutical companies are anticipated to increase their investments in AI-powered drug discovery platforms. Huatai Securities emphasized that the 'AI+Healthcare' sector is on track for substantial leapfrog development in 2025, urging investors to closely monitor and capitalize on related investment opportunities.